SNAPPER: Prospective Evaluation of Renal effects
We are inviting you to take part in this sub study because you have joined the SNAP platform, and you have a risk factor for developing injury to your kidneys.
This sub-study is being conducted in Australia.
Lead Investigator: Amy Legg - Brisbane Women's Hospital, Menzies School of Health
Email: amytherese.legg@menzies.edu.au
Please read the below information to learn more about the assessments and tests involved in this sub-study.
We will also be using results from your blood tests that are already being done by the hospital. We will not take any additional blood tests from you.
Risks:
Benefits:
You can withdraw from the sub study and/or from future use of your samples at any time, just notify a member of the SNAP study team.
If you withdraw, we will keep any information we have collected about you up until you withdraw. If you do not agree with this, you should not join this substudy.
Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia
SNAPstrat: Patient stratification using SAB sub-phenotypes
C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial
Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials
Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth